Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and more nimble. Headcount rationalization in R&D is rumored to be already underway, while more operational areas could potentially see significant manpower reductions.
Strategy Human Capital Companies

Pharma Q2 Results Preview: Johnson & Johnson And Novartis

The earnings season is on us again with two heavyweights of health care hoping to show strong second-quarter results, while giving a glimpse into their prospects for the second half of the year. It will be Novartis' first chance to talk with investors about a new US Senate report regarding the company's dealings with Trump lawyer Cohen.

Sales & Earnings Analysis Companies

Roivant Splashes Cash Again To License GSK Skin Disorder Drug

The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof to Dermavant, banking a hefty £150m up front and possibly another £100m after that.

Dermatology Deals Immune Disorders

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a fuller dataset and an external analysis of cardiovascular risk.

Clinical Trials Commercial Drug Safety
Advertisement


 Recent Tweets from Scrip


Pharma Asset Insights

Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene therapies and antisense oligonucleotides demand that all health care stakeholders make efforts to move into the next generation of patient care and centricity.

Pharma Asset Insights provides a compilation of insights and data-driven analysis.

Read now and discover more

RTSM/IRT: A Roadmap For Developing Systems That Address Current Frustrations

In a recent study commissioned by Oracle Health Sciences and conducted by Informa Pharma Intelligence, 254 clinical operations, trial management, and related functional professionals responded about the needs of study teams related to existing RTSM/IRT solutions.

Survey results include:

  • The most common frustrations associated with existing RTSM/IRT systems
  • The effect of RTSM/IRT integration into eClinical platforms
  • Opportunities for improving current RTSM/IRT systems
Download the Report

 

Commercial Explore this Topic

Set Alert for Commercial

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Deals Commercial Business Strategies

Alarm As Novartis Exits Antibiotics Space

The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."

Infectious Diseases Innovation Pricing Debate

Authorities Find Accounting Violation By Samsung BioLogics, Prosecutors To Probe

South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper. 

South Korea Commercial

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.

Intellectual Property Legal Issues

Flurry Of Marketing Collaborations Set India Deal Street Abuzz

In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.

India Commercial

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Mylan has priced its biosimilar version of pegfilgrastim at a 33% discount to Amgen's WAC for Neulasta, steeper than the 15% discount Pfizer initially offered for Inflectra. The commercial outcome for Fulphila could set the tone for future US biosimilars, which have yet to take off.

Biosimilars Launches

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Cancer Companies

EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus

By selling off its critical care business, EUSA Pharma gets needed funds and freedom to fully focus on oncology and rare diseases, its CEO tells Scrip.

Deals Companies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

14 Approvals To Look Out For In Q3

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Approvals Policy & Regulation Cancer

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

China India

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Pricing Debate Pricing Strategies

Trump Tries To Shame A Defiant Pfizer On Drug Pricing

President Trump called out Pfizer’s recent price increases on Twitter July 9. Pfizer was one of only four companies that took a second round of price increases in 2018, according to analysts at Morgan Stanley. CEO Read has long defended the industry's pricing practices, even as public criticism of the high drug prices has grown. 

Pricing Debate Pricing Strategies

Research & Development Explore this Topic

Set Alert for Research & Development

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals Research & Development

Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks

Lynovex, a reformulated version of a molecule which has been around for decades for a rare metabolic disease, has just succeeded in a Phase IIb study to treat exacerbations in cystic fibrosis. The mutation-agnostic therapy could improve on current treatments for breakthrough exacerbations, and reduce the associated long-term damaged.

Respiratory Rare Diseases

Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole

Positive top-line results from the Phase IIb DOVE study of Scynexis's SCY-078, and progress with a new intravenous formulation, suggest the US biotech's new triterpenoid could be the first of a new class of antifungal agents for serious infections.

 

Clinical Trials Gynecology & Urology

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic

Spun out from Oculeve in tandem with that company’s acquisition by Allergan, Oyster Point hopes to develop a nasal spray that can address the underlying cause of dry eye. It has two candidates on parallel courses in Phase II with a goal of choosing one to advance into Phase III.

Research & Development Ophthalmic
UsernamePublicRestriction

Register

Advertisement